4 false false false false false false false false false false true false false false false false false No description of principal activity 2024-01-08 Sage Accounts Production Advanced 2024 - FRS102_2024 31,000,000 14,000,000 202,046 17,202,046 17,202,046 xbrli:pure xbrli:shares iso4217:GBP 15397273 2024-01-08 2025-03-31 15397273 2025-03-31 15397273 2024-01-07 15397273 bus:Director4 2024-01-08 2025-03-31 15397273 core:WithinOneYear 2025-03-31 15397273 core:ShareCapital 2025-03-31 15397273 core:CapitalRedemptionReserve 2025-03-31 15397273 core:OtherReservesSubtotal 2025-03-31 15397273 core:RetainedEarningsAccumulatedLosses 2025-03-31 15397273 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-03-31 15397273 core:DisposalsRepaymentsInvestments core:Non-currentFinancialInstruments 2025-03-31 15397273 core:Non-currentFinancialInstruments core:OtherIncreaseDecreaseInInvestments 2025-03-31 15397273 core:CostValuation core:Non-currentFinancialInstruments 2025-03-31 15397273 core:Non-currentFinancialInstruments 2025-03-31 15397273 bus:Director1 2024-01-08 2025-03-31 15397273 bus:SmallEntities 2024-01-08 2025-03-31 15397273 bus:AuditExemptWithAccountantsReport 2024-01-08 2025-03-31 15397273 bus:SmallCompaniesRegimeForAccounts 2024-01-08 2025-03-31 15397273 bus:PrivateLimitedCompanyLtd 2024-01-08 2025-03-31 15397273 bus:FullAccounts 2024-01-08 2025-03-31 15397273 core:AllAssociates 2024-01-08 2025-03-31
COMPANY REGISTRATION NUMBER: 15397273
RQ Biotechnology Holdings Limited
Filleted Unaudited Financial Statements
31 March 2025
RQ Biotechnology Holdings Limited
Financial Statements
Period from 8 January 2024 to 31 March 2025
Contents
Page
Statement of financial position
1
Notes to the financial statements
2
RQ Biotechnology Holdings Limited
Statement of Financial Position
31 March 2025
31 Mar 25
Note
£
Fixed assets
Investments
5
17,202,046
Current assets
Cash at bank and in hand
19,860
Creditors: amounts falling due within one year
6
11,049
--------
Net current assets
8,811
-------------
Total assets less current liabilities
17,210,857
-------------
Capital and reserves
Called up share capital
1
Capital reserve
16,999,999
Other reserves
202,046
Profit and loss account
8,811
-------------
Shareholders funds
17,210,857
-------------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
For the period ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 12 August 2025 , and are signed on behalf of the board by:
M Westby
Director
Company registration number: 15397273
RQ Biotechnology Holdings Limited
Notes to the Financial Statements
Period from 8 January 2024 to 31 March 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Scale Space Building, 58 Wood Lane, London, W12 7RZ, England.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss. The financial statements are prepared in sterling, which is the functional currency of the entity.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods supplied and services rendered, stated net of discounts.
Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses. Loans and borrowings are initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment. If an arrangement constitutes a finance transaction it is measured at present value.
Share based payments
Share-based payment arrangements in which the group receives services as consideration for its own equity instruments are accounted for as equity-settled share-based payment transactions and measured at fair value using the Black Scholes model. The fair value of share-based payments awards granted to employees of subsidiaries is recognised as an increase in investment cost, with a corresponding increase in equity, over the period in which the employees become unconditionally entitled to the awards.
4. Employee numbers
The average number of persons employed by the company during the period amounted to 4 .
5. Investments
Shares in group undertakings
£
Cost
At 8 January 2024
Additions
31,000,000
Disposals
( 14,000,000)
Other movements
202,046
-------------
At 31 March 2025
17,202,046
-------------
Impairment
At 8 January 2024 and 31 March 2025
-------------
Carrying amount
At 31 March 2025
17,202,046
-------------
6. Creditors: amounts falling due within one year
31 Mar 25
£
Trade creditors
15
Amounts owed to group undertakings and undertakings in which the company has a participating interest
11,034
--------
11,049
--------
7. Related party transactions
Management fees charged to the subsidiary entity, RQ Biotechnology Limited, amounted to £13,000. The amount due to RQ Biotechnology Limited at 31 March 2025 was £11,034. During the period, the business of managing the portfolio of licensed assets was transferred from RQ Biotechnology Limited to the Company and subsequently demerged into a new commonly controlled entity, RQBio Covid Limited.